Today's Top Gainer
Note:Top Gainer - Nifty 50 More
Global pharmaceutical industry1
Global spending on medicines crossed US$ 1.2 Trillion in 2018; and is projected to grow at a compound annual growth rate (CAGR) of 3-6% in the next five years, reaching over US$ 1.5 Trillion by 2023. Growth in the global pharmaceutical market will continue to be led by the US and pharmerging markets.
While new product launches, especially specialty products, will be the key growth catalyst in developed markets, pharmerging market expansion will be driven by multiple factors. These factors comprise improving per capita income, increasing healthcare awareness, ageing population and rising incidence of chronic ailments. The product mix in the developed world will continue to shift towards specialty and orphan products. Emerging technologies are enabling healthcare providers to innovate and engage better with key stakeholders.
|Table 1 Global pharmaceutical spending and growth1|
|(US$ Billion)||CAGR (%)||(US$ Billion)||CAGR (%)|
|Rest of the world||119||3.2||130-160||2-5|
|Global pharmaceutical market||1,205||6.3||1,505-1,535||3-6|
Table 2 Global medicine spending by region and product types in 20231
|Spending||Original brands||Non-original brands||Unbranded||Over-the-counter (OTC) and other products||Total (US$ Billion)|
|Rest of world||56%||26%||8%||10%||130-160|
Outlook and emerging trends1,2
US spending was at US$ 486 Billion in 2018, while pharmerging markets spending was US$ 286 Billion. These two regions will be key contributors to global pharmaceutical growth.
Pharmaceutical spending in the top five western European markets (EU5) touched US$ 178 Billion in 2018; and is likely to grow at a sluggish pace in the 2018-2023 period, as compared to that of the previous five years. Government-mandated price reductions and slower uptake of new specialty products will be key reasons of this sluggish growth.
Chinas US$ 137 Billion pharmaceutical market is expected to grow at 3-6% by 2023, driven by improving insurance access, modernisation of hospital systems and expansion of primary care services.
Japans medicine spending was at US$ 86 Billion in 2018; and is expected to slow through 2023, on account of continued uptake of generics and government-mandated price reductions.
Uptake of specialty medicines will continue to rise in developed markets, driven by advancement of new and innovative targeted medicines, using immunology, gene therapy, monoclonal anti-bodies and other contemporary technologies. Share of specialty medicines in overall pharmaceutical spending will cross 50% by 2023 in most developed markets.
Healthcare providers are exploring technology investments in cloud computing, artificial intelligence and machine learning to ramp up productivity.
This trend is expected to gain further momentum in the coming years.
Growth enablers for the global pharmaceutical market1,345 Growing and ageing population:
Global population is projected to exceed 9.3 Billion by 2050, of which 21% will be accounted for by those aged 60 and above.
Longer life expectancy:
As individuals become increasingly health conscious and medical science continues to advance, life expectancy will increase. By 2040, Japan, Singapore,
Spain and Switzerland are projected to have a life expectancy rate in excess of 85 years, while 59 countries, including China, are expected to surpass a life expectancy of 80 years during that period.
Improving purchasing power: The middle-class population as well as per capita income continues to expand, driving demand for pharmaceutical products. This expansion is likely to be broad based, but more pronounced in Asia, particularly in China and India.
Greater prevalence of chronic diseases: Chronic disease prevalence is expected to rise to 57% by 2020-increasing the demand for healthcare products and services. Emerging markets will account for a majority share, as population growth is expected to be most significant in developing nations.
Research focus on orphan drugs: Growing research focus on rare disease therapies has resulted in a significant increase in new orphan drugs. The United States Food and Drug Administration (USFDA) approved 80 orphan indications in 2017 and 90 in 2018.
Growth in global pharmaceutical spending through 2023 will primarily be driven by developed markets and the accelerated adoption of new innovative products. Spending on medicines in developed markets is estimated to grow at 3-6% CAGR from US$ 800 Billion in 2018 to US$ 990-1,020 Billion in 2023. The US will continue to be an important contributor, with its medicine spending expected to remain higher that of the top five European economies.
All developed countries will show moderation in growth through 2023, as compared to the 2014-18 period. Specifically in the US, the positive impact of new specialty launches will be partly moderated by loss of patent protection on older products.
Table 3 Pharmaceutical spending of developed markets (US$ Billion)1
|Region/Country||2018||2014-2018 CAGR||2023||2019-2023 CAGR|
The US pharmaceutical market is set to exceed US$ 600 Billion by 2023. The key driver of this trend will be launch of new specialty products which will be partly offset by patent expiries, growth of biosimilars and slower rate of rise in new launch prices. There has been significant attention given to the launch prices of recently introduced drugs, especially given the shift in innovation towards specialty, orphan and oncology areas (that are often costlier).
Chart 2 US pharmaceutical spending growth1
The CAGR for the top five developed markets in Western Europe is likely to reduce to 1-4%, with overall spending expected to cross US$ 200 Billion in 2023. Government-led cost controls and decelerated growth in spend on new products will contribute to the slowing in pace vis-a-vis the 4.7% CAGR between 2014 and 2018, that was helped by spending on new products (especially oncology and viral hepatitis treatments).
Spending in Japan amounted to US$ 86 Billion in 2018, but over the next five years, spending on medicines is expected to continue to decline. This is largely due to the continued uptake of generics, despite higher spending on specialty products and an ageing population.
The government of Japan in 2014 set out a policy to achieve a rate of 80% of prescription volume of unbranded generics in the non-patented market by 2021. The resulting savings from generics is enabling a greater shift to specialty medicines without an overall increase in the countrys healthcare budget. Share of specialty spending in Japan is expected to rise from approximately 30% in 2018 to 41% in 2023.
Chart 3 Western Europe pharmaceutical spending growth1
Growth in global pharmaceutical spending through 2023 will primarily be driven by developed markets and the accelerated adoption of new innovative products. Spending on medicines in developed markets is estimated to grow at 3-6% CAGR from US$ 800 Billion in 2018 to US$ 990-1,020 Billion in 2023.
Spending on medicines in pharmerging markets was recorded at US$ 286 Billion in 2018 and is projected to grow at 5-8% CAGR through 2023 to reach US$ 355-385 Billion. A key driver to that end is increasing per capita uptake of medicines with a rise in patients affordability.
Table 4 Pharmaceutical spending and region-wise growth for pharmerging markets (US$ Billion)1
|Region/Country||2018||2014-2018 CAGR||2023||2019-2023 CAGR|
|Tier 2 markets||68||10.7%||91-95||7-10%|
|Tier 3 markets||86||11.3%||105-135||7-10%|
China is the largest pharmerging market registering pharmaceutical spending of US$ 132 Billion in 2018; and is likely to reach US$ 140-170 Billion by 2023. Spending is driven, in part, by reforms initiated by the Chinese central government to accelerate insurance access to rural and urban residents, as well as the expansion and modernisation of the hospital network and primary care services.
Indian pharmaceutical market1,2
India enjoys a key position in the global pharmaceutical industry. The country is the worlds largest supplier of generics, accounting for 20% of global exports. It supplies over 50% of global demand for various vaccines and 40% of the demand for generic products in the US. The domestic pharmaceutical market contributes to ~2% of the global industry in value and ~10% in volume terms. The domestic pharmaceutical industry has received foreign direct investment (FDI) worth ~US$ 16 Billion on a cumulative basis, between April 2000 and June 2018.
Indias pharmaceutical spending is predicted to grow at 8-11% CAGR in the 2019-23 period to reach a size of US$ 28-32 Billion. A part of this growth will depend on the ability of companies to align their product portfolio towards therapies for chronic diseases that are on the rise.
Increasing per capita income.
Growing penetration of health insurance.
Government thrust on improving penetration of modern medicines into rural areas and accelerating access of pharmaceutical products to the poor and low-income sections of the population.
Increased incidence of chronic ailments.
Changing lifestyle and consumption patterns.
Improving healthcare awareness.
Specialty medicines refer to those used in the treatment of chronic, complex or rare diseases and that require advanced scientific research and innovation. Given their significantly higher purchasing power and strong healthcare insurance coverage, developed markets account for a significant share of global spending on specialty products. Specialty represents a small share in pharmerging markets, given the relatively lower purchasing power, and is expected to rise marginally from 13% in 2018 to 14% by 2023. Specialty is expected to represent more than half of newly launched medicines globally over the next five years. A larger use of biomarkers to segment and treat appropriate patients will characterise these launches.
Spending on specialty medicines in developed markets accounted for US$ 336 Billion in 2018 and is estimated to rise to US$ 475-505 Billion in 2023. Specialty share of total spending across top 10 developed countries is likely to rise from 42% in 2018 to 50% in 2023. Almost 74% of this is expected to be led by the five largest specialty therapeutic classes: oncology, autoimmune, immunology, anti-virals and multiple sclerosis. In most developed markets, specialty spend continues to outpace that on other medicines.
Active Pharmaceutical Ingredients (API)7
APIs are chemicals and biologically active elements of drugs with a direct impact on cure, mitigation, treatment and prevention of diseases. The worldwide API market is likely to exceed US$ 225 Billion by 2024-a 6% CAGR for the forecast period.
The market has witnessed growth through the decades, due to an ever-increasing use of medication and biologics for disease management. Other drivers include increasing incidence of chronic ailments, growing volumes of generic drugs worldwide and rising technological advancements in API manufacturing.
Consumer healthcare providers deal with products in wellness, oral health, nutrition, skin health. These include over-the-counter (OTC) drugs. Globally, a large number of acquisitions, mergers and shutdowns has resulted in industry consolidation, with market share being concentrated within the top 10 firms. The Global OTC market was valued at $135 Billion in 2018. Two top markets, the US (US$34 Billion) and China (US$25 Billion) accounted for ~44% of the global market. Vitamins, minerals & supplements and the cough, cold & allergy segments account for more than 50% sales of OTC products globally.
There is a global trend towards self-care, self-medication, awareness for wellness and preventive medicine, along with a rise in disposable income, demand for personalised products, acceptance of e-commerce retail and shift to OTC products. This trend is expected to drive the growth of the industry in future.
WORLD OF SUN PHARMA
Sun Pharmaceutical Industries Limited including its subsidiaries and associates (Sun Pharma) is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
Sun Pharma enjoys a vertically integrated business, economies of scale and good talent management practices that enable it to deliver quality products at affordable prices. The Company is deepening its global footprint as a highly trusted manufacturer of specialty products, branded generics, complex and pure generics, OTC products, anti-retrovirals (ARVs) and APIs.
It is expanding its footprint among consumers and healthcare professionals in 100+ countries, and offers a portfolio of 2,000+ products, globally, in a full range of dosage forms.
This includes tablets, capsules, injectables, ointments, creams and liquids, nasal sprays and hormones, among others.
Sun Pharma has 44 manufacturing sites approved by global health regulatory agenciessupported by a worldwide supply chainand multiple research and development (R&D) facilities across the world, investing 6.9% of its sales in R&D. It has a diverse employee base of 32,000+ individuals across 50 nationalities worldwide.
Table 5 Major acquisitions and joint ventures (JVs)
|1997||Acquired Caraco||USA||Entry into the US generics market|
|2010||Acquired Taro Pharmaceutical Industries Ltd.||Israel||Enhance presence in the US generics market, especially in the dermatology segment|
|2012||Acquired DUSA Pharma, Inc.||USA||Access to branded dermatology product|
|2013||Acquired URLs generics business||USA||Addition to the US generics portfolio|
|2014||Acquired Pharmalucence||USA||Access to sterile injectable capacity in the US, supported by R&D capabilities|
|2014||In-licensing agreement with Merck for ILUMYA, a biologic for psoriasis||Global||Strengthen the specialty product pipeline|
|2015||Sun Pharma-Ranbaxy merger||Global||Further strengthen position as the fifth largest global specialty generics pharmaceutical company and the No. 1 pharmaceutical company in India, with strong positioning in emerging markets|
|2015||Distribution agreement with AstraZeneca||India||Distribution services agreement in India for brand Axcer (brand of ticagrelor; used for the treatment of acute coronary syndrome)|
|2015||Acquisition of InSite Vision||USA||Strengthen branded ophthalmic portfolio in the US|
|2016||Distribution agreement with AstraZeneca||India||Distribution services agreement in India for brands Oxra and Oxramet (brands of dapagliflozin; used for diabetes treatment)|
|2016||Acquired 14 brands from Novartis||Japan||Entry into Japan|
|2016||Licensing agreement with Almirall for ILUMYA for psoriasis||Europe||Strengthen the distribution of ILUMYA in Europe|
|2016||Acquired Biosintez||Russia||Access to local manufacturing capability to enhance presence in the Russian market|
|2016||Acquired global rights for Cequa and Odomzo||Global||Strengthen specialty pipeline in the ophthalmology and oncology space|
|2018||Acquired Pola Pharma in Japan||Japan||Access to the Japanese dermatology market|
Sustainable value-creation model
8th largest generics company in the US with a strong pipeline (118 ANDAs and 8 NDAs awaiting approval).
Presence in generics, specialty and branded segments with 450+ approved products.
FY19 sales: 106,713 Million.
Indian branded generics business
Ranked No. 1 across 11 classes of doctors.
Leading position in high growth chronic therapies.
Specialises in technically complex products.
FY19 sales: 73,483 Million.
Presence in ~100 countries across Africa, Americas, Asia and Eastern and Central Europe.
Key focus geographies include Brazil, Mexico, Russia, Romania, South Africa and complementary and affiliated markets.
FY19 sales: 53,624 Million.
Create sustainable revenue streams
Enhance share of specialty business globally.
Achieve differentiation by focusing on technically complex products.
Focus on key markets; achieve critical mass.
Ensure sustained compliance with global regulatory standards.
Optimise operational costs.
Rationalise vertically integrated operations.
ANDA: Abbreviated new drug application : NDA: New drug application : DMF: Drug master file : CEP: Certification of Suitability
Sun Pharmas business model comprises four crucial business features to help achieve higher efficiencies and drive sustainable growth. The Company is strategically poised to capitalise on the emerging opportunities in the global pharmaceutical sector, to deliver consistent long-term stakeholder value.
Rest of world
Presence across majority of markets in Western Europe, Canada, Japan, Australia and New Zealand.
Products include differentiated offerings for hospitals, injectables and generics for retail market.
Portfolio of long-listed products servicing the Japanese market.
FY19 sales: 34,554 Million.
Global consumer healthcare business
Among the top 10 consumer healthcare companies in India.
Operates in 20+ countries.
Backward integration provides cost competitiveness and supply reliability.
Portfolio of 300+ approved DMF/CEP products.
Balance profitability and investments for future
Increase contribution of specialty and complex products.
Future investments directed towards differentiated products.
Use acquisitions to bridge critical capability gaps.
Focus on access to products, technology and market presence.
|Table 6 Consolidated|
|Return on net worth||%||6.4||5.5||18|
|Inventory turnover (on cost of goods sold)||1.0||1.1||-8|
|Interest coverage ratio||times||10.0||9.6||5|
|Operating profit margin||%||20.7||19.9||4|
|Net profit margin||%||9.3||8.0||16|
|Table 7 Standalone|
|Ratios||Unit||FY18||Variance (%)||Reasons if variance is more than 25%|
|Return on net worth||%||3.6||1.4||161||Return on net worth is higher for the year ended March 31, 2019 due to higher profit after tax|
|Inventory turnover (on cost of goods sold)||times||1.3||1.7||-21|
|Interest coverage ratio||times||4.6||4.2||10|
|Operating profit margin||%||12.6||8.5||49||On account of better revenue from contracts with customers which grew by 11%, along with cost containment|
|Net profit margin||%||8.3||3.5||140||On account of increased total revenue from operations by 14%, along with cost containment|
FY19 operational highlights
In April 2018, Sun Pharma entered the anti-fungal powder OTC category in India with ABZORB. The brand was co-promoted across prescription and OTC channels through a 360 marketing campaign comprising TV, print and digital, to expand consumer outreach and drive growth. ABZORB has a unique combination of talc and starch that ensures superior sweat absorption.
It also contains clotrimazole-one of the best-in-class anti-fungalsto help treat infection and prevent its recurrence. The new packaging with an angular dispensing nozzle enhances consumer experience through targeted application.
In May 2018, Sun Pharma received USFDA approval for YONSA (abiraterone acetate), a novel formulation in combination with methylprednisolone to treat patients with metastatic castration-resistant prostate cancer (mCRPC). This approval has further strengthened the Companys oncology portfolio in the US.
In June 2018, Sun Pharma received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its Halol facility in Gujarat (India) during the previous financial year. The receipt of the EIR implies that the issues contained in the Warning Letter dated December 2015 have been addressed. New ANDA approvals have commenced from the facility post the receipt of EIR.
In July 2018, Sun Pharma announced Bollywood actor Akshay Kumar as its brand ambassador for Revital H. He is known for his high energy levels and was a natural fit for the product, which is Indias leading and most trusted health supplement for over two decades. The Company launched a 360 marketing campaign featuring the actor and the brand that helps keep ones energy and stamina high throughout the day.
In July 2018, Sun Pharma announced the USFDA approval for INFUGEM (gemcitabine in 0.9% sodium chloride injection) 10 mg/mL, for intravenous use in a ready-to-administer (RTA) bag. INFUGEM uses a proprietary technology, which allows cytotoxic oncology products to be premixed in a sterile environment and supplied to the prescribers in RTA infusion bags.
It involves dose banding practice, whereby standardised doses of intravenous cytotoxic drugs are used for ranges (or bands) of doses calculated for individual patients. The RTA bags will provide greater safety by preventing problems of over-dosing or under-dosing, by eliminating contamination risk that can lead to infections, and by taking care of problems associated with and precautions to be taken while, handling cytotoxic drugs by healthcare providers.
In July 2018, DUSA Pharmaceuticals, Inc., (DUSA) a wholly owned subsidiary of Sun Pharma, announced that it filed trade secret misappropriation and tortious interference claims in an ongoing patent infringement lawsuit against Biofrontera Inc. The patents-in-suit concerned an apparatus and method for photodynamic therapy (PDT) as well as an equipment for it.
Pioneered by DUSA, PDT combines a drug with a light source to treat disease conditions. In December 2018, DUSA was granted preliminary injunctive relief by a federal district court prohibiting defendant Biofrontera (including Biofrontera Inc., Biofrontera Bioscience GmbH Biofrontera Pharma GmbH, and Biofrontera AG) from using DUSAs confidential and proprietary trade secret information.
In August 2018, Sun Pharma received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the USFDA. CEQUA increases tear production in patients with dry eyes. It is the first and only approved dry eye treatment to combine cyclosporine A with nanomicellar technology.
In August 2018, Sun Pharma launched a Kapspargo Sprinkle (metoprolol succinate) extended-release sprinkle formulation in the US. The product will help treat hypertension (high blood pressure), angina pectoris (chest pain) and heart failure. These extended-release coated pellets can be sprinkled over soft food or administered via a nasogastric tube to facilitate long-term once-daily administration for patients who experience difficulty while swallowing.
In August 2018, the Company announced the launch of Volini Maxx, Indias strongest pain relief spray. It also signed Virat Kohli, captain of Indian cricket team as Volinis brand ambassador.
In September 2018, Sun Pharma announced USFDA approval for the NDA of XELPROS (latanoprost ophthalmic emulsion) 0.005%. The medicine is used for the reduction of elevated intraocular pressure (IOP or pressure inside the eye) in patients with open-angle glaucoma or ocular hypertension. XELPROS is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK), a commonly used preservative in topical ocular preparations. It was in-licensed by Sun Pharma from Sun Pharma Advanced Research Company Ltd. (SPARC) in June 2015; and is developed using SPARCs proprietary swollen micelle microemulsion (SMM) technology.
In September 2018, Sun Pharma announced that its European partner, Almirall, received the European Commission (EC) approval for ILUMETRI (tildrakizumab) to treat adults with moderate-to-severe chronic plaque psoriasis, who are candidates for systemic therapy.
In September 2018, Sun Pharma received the Australian Therapeutic Goods Administration (TGA) approval for its specialty product, ILUMYA (tildrakizumab) to treat adults with moderate-to-severe plaque psoriasis and are candidates for systemic therapy.
In October 2018, Sun Pharma launched ILUMYA (tildrakizumab-asmn) 100 mg/mL in the US for treating moderate-to-severe psoriasis.
In November 2018, Sun Pharma entered into a definitive agreement to acquire Pola Pharma Inc. (Pola Pharma), a Japanese pharmaceutical company. Pola Pharma is engaged in R&D, manufacture, sale and distribution of branded and generic products in Japan. Its portfolio primarily comprises dermatology products and it has two manufacturing facilities in Japan with capabilities to manufacture topical products and injectables, along with R&D capabilities to develop new technologies and formulations.
Pola Pharma had annual revenues of approximately US$ 108 Million and net loss of US$ 7 Million for 12 months ended December, 2017 on a consolidated basis. This acquisition strengthens Sun Pharmas presence in Japan and accelerates access to the Japanese dermatology market.
Sun Pharmas sustained focus is on growing each of its businesses faster than the market in which they operate.
Its global specialty initiatives will supplement this objective as an additional growth engine. Although the US generics industry continues to face pricing pressure, the industry has started responding to these challenges by rationalising product portfolios and discontinuing non-remunerative products. Generics will continue to be an integral part of the solution to control global healthcare costs as well as play an important role in overall healthcare management.
Sun Pharma will continue to invest in the generic business with a focus on developing differentiated complex generics and building a product pipeline across markets. Its global specialty business is also expected to ramp up gradually. Investments in branding and promotion of specialty products and in funding clinical trials for specialty products will continue. For FY20, the Company expects its consolidated revenues to grow by low-to-mid teens, while R&D investments are estimated at ~8-9% of sales.
Business segment review
Sun Pharma is the eighth largest generic pharmaceutical company in the US, with presence across generics, specialty, branded and OTC segments. It offers a comprehensive portfolio of 453 ANDAs and 51 NDAs approved across multiple therapies.
The Companys key focus areas encompass central nervous system (CNS), dermatology, cardiology, oncology and ophthalmic, among others. It has integrated USFDA-approved on-shore as well as off-shore manufacturing facilities that produce a variety of dosage forms, including liquids, creams, ointments, gels, sprays, injectables, tablets, capsules and drug-device combinations.
Strong product pipeline in the US
As on March 31, 2019, Sun Pharma had 118 ANDAs and 8 NDAs pending USFDA approval, including a combination of complex generics, patent challenge opportunities and pure generics.
|Table 8||Journey in the US-key milestones|
|FY98|| Entered the US market through Caraco acquisition.|
|FY10|| Acquired Taro Pharma to penetrate the US dermatology market.|
|FY13|| Acquired DUSA to enter the branded specialty dermatology market.|
|FY15|| In-licensed Ilumya (tildrakizumab)-strengthened specialty dermatology portfolio by gaining access to global rights including the US.|
|FY16|| Strengthened specialty ophthalmic portfolio with the acquisition of InSite Vision.|
|FY17|| Filed tildrakizumab in the US and Europe.|
| Acquired Ocular Technologies-gaining access to Cequaa product for treating dry eyes.|
| Launched BromSite in the US ophthalmology segment.|
| Acquired odomzo, a branded oncology product from Novartis.|
|FY18|| Launched Odomzo in the US.|
| Obtained USFDA approval for Ilumya.|
|FY19|| Launched specialty products-Ilumya, Yonsa and Xelpros-in the US.|
| Received USFDA approval for Cequa.|
Revenue from the US increased by 22% to 106,713 Million.
Key growth drivers include increase in generic sales, incremental contribution from specialty product launches and a favourable foreign exchange rate.
The US generic market continued to be highly competitive and witnessed price erosion, driven by higher bargaining power of customers and faster pace of generic approvals from the USFDA.
Patent expiries and the US governments focus on reducing healthcare costs will continue to favour the growth of low-cost generics in the US market.
Going forward, the Company will focus on:
Growing the share of specialty product revenues in its portfolio.
Emphasising on complex generics and high-entry barrier segments.
Ensuring a diversified offering to customers across multiple dosage forms.
Sustaining and improving high service standards for customers.
Sun Pharma continues to be the undisputed industry leader in India, enjoying 8.2% share of the market. The Company is also the market leader in the chronic segment.
It specialises in technically complex products and offers a comprehensive therapy basket. It enjoys a strong brand positioning with 30 brands featuring in the countrys top 300 pharmaceutical brands list.
Revenue from the Indian branded generic business declined by 8.5% to 73,483 Million.
The Company has decided to transition its India formulations distribution business from a third- party distributor to the Companys wholly-owned subsidiary with effect from April 1, 2019. As a part of this strategy shift, the Company undertook a one-time adjustment relating to sales return from the distributor and lower invoicing to this distributor, totalling ~10,850 Million. This has led to the year-on-year decline in sales. Excluding this one-time impact, the India formulations revenues would have grown by about ~5% year on year.
The Company has a 9,500+ strong field force that ensures it reach to 4 lakh+ doctors across India. The Companys well-trained team of sales representatives, powered by scientific knowledge, has a strong performance track record with the highest productivity in the industry.
Table 9 Leadership in prescription rankings10
|Specialist||February 2018||February 2019|
Indias pharmaceutical market growth is expected to be driven by increasing per capita income, rising healthcare awareness, higher incidence of chronic ailments and gradually widening insurance coverage. Despite these tailwinds, the pharmaceutical companies face key challenges, which include government-mandated price controls, regulatory changes and intense competitiveness.
Sun Pharmas key priorities comprise:
Consistent innovation as a definite roadmap to ensure high brand equity with doctors.
Product basket enhanced developed through own development and in-licensing.
Focus on improving productivity to maintain industry leadership.
The focus markets for this segment include Brazil, Mexico, Russia, Romania, South Africa and complementary and affiliated markets.
The Company offers an extensive array of branded products and leverages its strong marketing infrastructure through its ~2,300-member strong sales force. This enables enduring relationships with doctors and medical practitioners.
The Company enjoys local manufacturing facilities, enabling reduction in logistics cost, across 7 countries.
Revenue from emerging markets increased by 11% to 53,625 Million.
Key markets, which contributed to the growth were Romania, South Africa, Brazil, Malaysia and Bangladesh, coupled with a favourable foreign exchange rate.
The favourable macroeconomic parameters of emerging markets offer encouraging long-term potential, which is expected to be partly offset by the various government efforts to make pharmaceutical products more affordable for all.
Going forward, the Company will:
Focus on developing and commercialising more products across therapeutic segments to exploit growth opportunities.
Explore organic and inorganic options to widen and deepen footprint in key markets.
Strengthen business profitability by launching complex products and reducing presence in low profitable, non-core product segments.
REST OF THE WORLD: WESTERN EUROPE, CANADA, JAPAN, AUSTRALIA, NEW ZEALAND AND OTHER MARKETS
Sun Pharma is among the leading Indian companies that has a presence across major markets of Western Europe, Canada, Australia, New Zealand and Japan, among others. Across these geographies, the Company offers a wide range of products, including injectable and hospital products, as well as products for retail market. It also has a portfolio of long-listed products in the Japanese market.
The Company primarily focuses on the development and commercialisation of complex generics and differentiated products for these markets. It has adopted a distribution-led business model to enhance its reach across these markets and caters to them through local manufacturing in Canada, Japan, Israel and Hungary, along with support from its India units.
Expanding presence in Japan
Sun Pharma had acquired 14 established prescription brands from Novartis in March 2016. During FY19, it acquired Pola Pharma in Japan, to strengthen its presence in the Japanese dermatology segment.
Revenue from rest of the world increased by 16% to 34,554 Million.
The growth was driven in part by contribution from the Pola Pharma acquisition in Japan, increase in sales in some of the western European markets and a favourable exchange rate.
With demographic changes across these markets, especially in Western Europe and Japan, enhanced drug demand for geriatric care and chronic diseases will drive pharmaceutical consumption. Additionally, the adoption of newer specialty products as well as government policies to promote low-cost generics will propel growth in these markets.
Sun Pharma will focus on:
Ramping up its presence in Japan.
Commercialising its specialty products, especially Ilumya, in key markets either on its own or through partnerships.
GLOBAL CONSUMER HEALTHCARE BUSINESS
Sun Pharma ranks among Indias top 10 consumer healthcare companies. Globally, it operates in 20+ countries, of which Romania, Russia, South Africa, Nigeria, Myanmar, Ukraine, Poland, Thailand, Belarus, Kazakhstan, Morocco and the UAE are the focus markets. The Company is also counted among the top 10 consumer healthcare companies in Romania, Nigeria and Myanmar.
Indias consumer healthcare market will be driven by the emerging middle class and rising healthcare consumption. Emerging markets are expected to sustain growth steered by enhanced healthcare awareness.
Capitalising on these enablers, Sun Pharma will:
Continue to invest in the accelerating OTC business across key markets through brand building.
Focus on distribution expansion through brand extensions.
Expand presence across OTC sub-categories in various markets.
Sustain leadership in existing markets by offering innovative products and packaging.
Evaluate new emerging markets for entry.
ACTIVE PHARMACEUTICAL INGREDIENTS (API) BUSINESS
*as on March 31, 2019
Sun Pharma started producing APIs in 1995 to strengthen backward integration to drive cost competitiveness and supply reliability.
The API business is of strategic importance for Sun Pharma, as a significant portion of the API production acts as inputs for its formulations business. Besides captive consumption, the Company also supplies APIs to external customers across many international markets.
Revenue from Active Pharmaceutical Ingredients (API) business increased by 24% to 17,303 Million.
Key growth drivers include new contracts, better realisations and a favourable foreign exchange rate.
Key focus areas for the future will be:
Timely development and commercialisation of strategic APIs for captive consumption.
Expansion in the scale and scope of API operations.
Development and sustenance of enduring supply relationships with customers.
Sun Pharma has consistently invested in R&D for sustainable value creation. It services both regulated and emerging pharmaceutical markets with a diverse product range of branded and generics products. The Companys R&D capabilities enable it to develop technology-intensive products and deliver them at affordable prices across international markets.
Sun Pharmas R&D centres are equipped with cutting-edge technologies, where its scientists develop generics, difficult-to-make technology-intensive products, APIs and novel drug delivery systems (NDDS). Additionally, the Company is focusing on the development of new chemical entities (NCEs) for global markets and has made significant investments in this domain. It also has a dedicated intellectual property rights (IPR) team, with internal and external lawyers, that supports its R&D efforts.
The Company has the capability to develop and commercialise a wide product range with successful offerings across different dosage forms such as gels, injectables, sprays, ointments, liquids and oral products, among others. Sun Pharma also manufactures liposomal products, auto-injectors, lyophilized injections, nasal sprays, and controlled release dosage forms.
Sun Pharma is focusing on the development of non-infringing formulations and expansion of the specialty/complex products portfolio. Its R&D spend is sustained by strong cashflows and large scale of the Company.
Going forward, the Companys R&D efforts will be focused at:
Developing complex/differentiated generic products for global markets.
Developing specialty products to enhance the specialty portfolio.
Chart 8 Consistent investments in R&D
Global manufacturing competence
Sun Pharma enjoys world-class production facilities spanning the five continents of Asia, Europe, Africa, North America and Australia. It owns 44 state-of-the-art manufacturing units that produce formulations and APIs. The Company enjoys vertically integrated operations that equip it to maintain a high-quality and low-cost value chain for timely market entry across geographies.
It has manufacturing units located in India, the US, Canada, Japan, Hungary, Israel, Russia, Egypt, Bangladesh, Nigeria, South Africa, Malaysia and Australia. These facilities are responsible for seamless production of oncology, hormones, peptides, controlled substances and steroidal drugs. They also manufacture generics, branded generics, specialty products, OTC products, ARVs and APIs, along with intermediates in the full range of dosage forms: tablets, capsules, injectables, ointments, creams and liquids.
The Company has an expert team of regulatory affairs specialists, who are well-versed with the globally-relevant regulatory policies and procedures. They are experienced in timely filing of dossiers and concurrently managing the regulatory queries and timelines of regulatory authorities.
Sun Pharma meticulously follows global manufacturing standards and many of its manufacturing units are certified by regulatory authorities like the USFDA, the European Medicines Evaluation Agency (EMEA), the UK Medicines and Healthcare Products Regulatory Agency (MHRA), Australias Therapeutic Goods Administration (TGA), South Africas Medicines Control Council (MCC) and Germanys Federal Institute for Drugs and Medical Devices (BfArM).
The Company also enjoys certifications by the Brazilian Health Regulatory Agency (ANVISA), the World Health Organization (WHO), South Koreas Ministry of Food and Drug Safety, and Japans Pharmaceuticals and Medical Devices Agency. It emphasises on 24x7 compliance to Current Good Manufacturing Practice (cGMP) regulations, which is vital for a global business.
|Table 10||Global Manufacturing Capability|
|Finished dosage manufacturing||API manufacturing|
|Total number of sites||30||14|
|Locations||India (14)||India (9)|
|USA (4)||Australia (2)|
|Japan (2)||Israel, USA and Hungary (1 each)|
|Canada, Hungary , Israel, Bangladesh, South Africa, Malaysia, Romania, Egypt, Nigeria and Russia (1 each)|
|Capability|| Orals: Tablets/Capsules, semisolids, liquids and suppository.|| Controlled substances manufactured in Australia.|
| Injectables/Sterile: Vials, ampoules, pre-filled syringes, gels, lyophilized units, dry powder, eye drops and aerosols.|| Standalone units for peptides, anti-cancer, steroids and sex hormones.|
| Topicals: Creams and ointments.|
Building an empowered team
Sun Pharma has a global strength of 32,000+ permanent team members across 50 different nationalities. It considers its people vital to its success and thus, endeavours to provide them with a congenial work culture that promotes work-life balance, provides growth opportunities and rewards and recognises talent.
The Company undertakes significant measures to help its people develop various skills through different training programmes. Sun Pharma promotes a culture of inclusive growth in the organisation to enrich knowledge and make its people future ready.
Quality is sacrosanct at all Sun Pharma R&D centres, manufacturing units and testing and distribution facilities. The Company is committed to implementing a robust quality management system and sustains a culture of operational excellence and meeting and exceeding stakeholder expectations.
Sun Pharma believes in the motto of putting patients first and its global Quality Management Team ensures every product complies with internationally accepted good practices and standards of quality, purity, efficacy and safety.
The Company has put stringent checks in place to conform to global quality standards and ensures compliance with the requirements of various regulators. It has cGMP certifications from various global regulatory authorities like USFDA, EMA, WHO and TGA, among others.
Sun Pharma has well-trained personnel for quality control at each site, who, along with a regulatory affairs department, ensure strict adherence to quality systems and procedures. The teams are guided by a Corporate Quality Unit, which oversees the translation of the latest GMP updates to guidelines, standard operating procedures (SOPs) and protocols. The Companys manufacturing plants are audited by an autonomous Corporate Compliance Department to set up 24x7 compliance and conformance.
Going ahead, Sun Pharma will continue to ensure 24x7 compliance to cGMP as an imperative for a global business. It will continue to enhance systems, processes and human capabilities to ensure compliance with global regulatory standards.
During the year, the USFDA granted an EIR to the Companys Halol facility, thus lifting the warning letter issued to the facility in 2015. Post the receipt of the EIR, the Company has started receiving new approvals from USFDA for the US market.
|Table 11 SWOT analysis|
|Strengths||Opportunities||1 Threats and weaknesses|
| Global presence-4th largest global specialty generic company.|| Global efforts to reduce healthcare costs augur well for companies like Sun Pharma.|| Challenging US generic pricing environment driven by customer consolidation and faster pace of generic drug approvals by the USFDA.|
| Largest company in India|| Favourable macroeconomic variable for India and emerging markets are likely to ensure reasonable volume growth for pharmaceutical products in these markets.|| Continuous upgradation of cGMP manufacturing standards by global regulatory agencies requires constant upgradation of facilities, resulting in higher compliance costs for the industry.|
| AmongthelargestIndian pharmaceutical company in emerging markets.|
| AmongthelargestIndian pharmaceutical company in Japan.|| Contribution of specialty products is expected to increase in developed markets over the medium to long term.|
| Government-mandated price controls on pharmaceutical products.|
| Strong R&D skillsets to develop technologically complex products in the generic and specialty space.||Sun Pharma forayed into this segment some years back; and is in the process of gradually ramping up this business as an additional growth engine.|| The specialty initiative entails high upfront investments for long-term benefits, thus impacting the short-term profitability|
| Ability to drive growth and profitability through a pragmatic mix of organic and inorganic initiatives.|| Growing penetration of generics in Japan and opening of the China market, present a good long-term opportunity for Indian companies including Sun Pharma.|| Significant volatility in the forex market, especially for emerging market currencies, may adversely impact growth reported for a particular period.|
| Ability to supply high-quality products at affordable prices.|
The Company believes that internal control is a necessary prerequisite of governance and that freedom should be exercised within a framework of checks and balances.
Sun Pharma has a well-established internal control framework, which is designed to continuously assess the adequacy, effectiveness and efficiency of financial and operational controls. The management is committed to ensure an effective internal control environment, commensurate with the size and complexity of the business, which provides an assurance on compliance with internal policies, applicable laws, regulations and protection of resources and assets.
Global Internal Audit (GIA)
An independent and empowered GIA at the corporate level carries out risk-focused audits across all businesses (both in India and overseas), to ensure that business process controls are adequate and are functioning effectively. These audits include reviewing finance, operations, safeguarding of assets and compliance related controls. Areas requiring specialised knowledge are reviewed in partnership with external subject matter experts.
GIAs functioning is governed by the Audit Charter, duly approved by the Audit Committee of the Board, which stipulates matters contributing to the proper and effective conduct of the audit. The audit processes are fully automated on a SunScience tool which integrates audit, Internal Financial Controls (IFC) and Enterprise Risk Management (ERM) modules.
The Companys operating management closely monitors the internal control environment and ensures that the recommendations of GIA are effectively implemented.
The Audit Committee of the Board monitors performance of GIA, periodically reviews key findings and provides strategic guidance.
Statements in this Management Discussion and Analysis describing the Companys objectives, projections, estimates, expectations, plans or predictions or industry conditions or events are forward-looking statements within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. Important factors that could make a difference to the Companys operations include global and Indian demand supply conditions, finished goods prices, feedstock availability and prices, competitors pricing in the Companys principal markets, changes in Government regulations, tax regimes, economic conditions within India and the countries within which the Company conducts businesses and other factors, such as litigation and labour unrest or other difficulties. The Company assumes no responsibility to publicly update, amend, modify or revise any forward-looking statements, based on any subsequent development, new information or future events or otherwise except as required by applicable law. Unless the context otherwise requires, all references in this document to we, us or our refers to Sun Pharmaceutical Industries Limited and consolidated subsidiaries.
1. IQVIA Institute
2. 2019 Global health care outlook (Deloitte)
3. 2017 United Nations World Population Prospects
4. The Lancet (Global Health Metrics, Volume 392, Issue 10159, P2052-2090, November 10, 2018)
5. World Health Organisation
6. India Brand Equity Foundation
8. Nicholas Hall 2018
9. AIOCD AWACS MAT-March 2019
10. SMSRC data-March 2019